BSE filing, NSE: ASTRAZEN. Summary written from the filing by ALFA Finder's alert engine.
AstraZeneca Pharma India Ltd: key numbers
- Share price
- ₹6,302.00
- Market cap
- ₹15,755 Cr
- Revenue (annual)
- ₹2,276 Cr
- Net profit (annual)
- ₹187.5 Cr
- P/E (TTM)
- 92.9×Sector 48.7×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 2.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from AstraZeneca Pharma India Ltd
All →AstraZeneca Pharma India Other Announcement
AstraZeneca Pharma India filed its quarterly shareholding pattern for the period ended 30 September 2026. Promoter and promoter group hold 75% of total equity.
AstraZeneca Pharma India Board Meeting Date
AstraZeneca Pharma India scheduled its board meeting for 5 Nov 2026 to approve Q2/H1 FY27 results. The trading window remains closed until 7 Nov 2026.
AstraZeneca Pharma India Capacity Expansion
AstraZeneca Pharma India inaugurated a new corporate office in Mumbai, covering 25,600 sq ft. This expansion strengthens the company's commercial operations and footprint in India.
- office space
- 25600.0 sq ft
AstraZeneca Pharma India Annual General Meeting
AstraZeneca Pharma India Ltd declared the voting results of its postal ballot, confirming the appointment and designation change of certain non-executive directors.
AstraZeneca Pharma India Other Announcement
NSE Sustainability Ratings and Analytics assigned AstraZeneca Pharma India an ESG rating of 73 for FY 2025-26. The rating was independently prepared without company engagement.
AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma India Limited received an order from the ROC, Bengaluru, imposing a total penalty of ₹0.03 Crore for a delayed filing. The company is evaluating next steps.
- Value
- ₹0.03 Cr
- From
- Registrar of Companies, Bengaluru, Karnataka
Other board meeting date announcements
All →Prismx Global Ventures Board Meeting Date
Prismx Global Ventures scheduled a board meeting for 4 November 2026 to consider unaudited standalone and consolidated results for Q2 and H1 ended 30 September 2026. The trading window remains closed until 48 hours after results.
Sun Retail Board Meeting Date
Sun Retail intimates a board meeting on 5 November 2026 to consider unaudited standalone half-year results ended 30 September 2026. The agenda is proposed only and no results are yet approved.
Mehul Colours Board Meeting Date
Mehul Colours intimates a board meeting on 7 November 2026 to consider unaudited half-year financial results ended 30 September 2026. The agenda is proposed only and no results are yet approved.
Paras Petrofils Board Meeting Date
Paras Petrofils Limited has intimated a board meeting on 05 Nov 2026 to consider unaudited standalone quarterly results for September 2026. Trading window closes 01 Oct to 09 Nov 2026.
Medplus Health Services Board Meeting Date
MedPlus Health Services scheduled a board meeting for 6 November 2026 to consider a share buy-back. The trading window for designated persons closes from 30 October 2026.
Capfin India Board Meeting Date
Capfin India will hold a board meeting on November 4, 2026 to consider unaudited results. The meeting agenda is proposed only, with results not yet approved.